Arie Belldegrun - Jun 12, 2024 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Director
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Stock symbol: DNA
Transactions as of: Jun 12, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/14/2024, 04:26 PM
Previous filing: May 20, 2024
Next filing: Jun 26, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Options Exercise		+105K	+117.4%		195K	Jun 12, 2024	Direct	F1
holding	DNA	Class A Common Stock						500K	Jun 12, 2024	By Bellco Legacy LLC	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Restricted Stock Units	Options Exercise		-105K	-100%		0	Jun 12, 2024	Class A Common Stock	105K	$0.00	Direct	F1, F3
transaction	DNA	Restricted Stock Units	Award	$0	+433K		$0.00	433K	Jun 13, 2024	Class A Common Stock	433K	$0.00	Direct	F1, F4
transaction	DNA	Stock Option	Award	$0	+571K		$0.00	571K	Jun 13, 2024	Class A Common Stock	571K	$0.46	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2	Bellco Legacy LLC is owned and managed by trusts controlled by the Reporting Person and Rebecka Belldegrun.
F3	In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
F4	The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date.
F5	In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000.